Insights from the breast cancer screening trials: How screening affects the natural history of breast cancer and implications for evaluating service screening programs

Breast Journal

Volumn 21, Issue 1, 2015, Pages 13-20

  Tabár, Lászlõ ^a   Yen, Amy Ming Fang ^b   Wu, Wendy Yi Ying ^c   Chen, Sam Li Sheng ^b   Chiu, Sherry Yueh Hsia ^d   Fann, Jean Ching Yuan ^e   Ku, May Mei Sheng ^c   Smith, Robert A ^f   Duffy, Stephen W ^g   Chen, Tony Hsiu Hsi ^c  

^a FALUN HOSPITAL   (Sweden)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e KAINAN UNIVERSITY   (Taiwan)

^f AMERICAN CANCER SOCIETY   (United States)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

advanced stage; breast cancer; early detection; mortality; screening

Indexed keywords

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; FOLLOW UP; HEALTH PROGRAM; HISTORY; HUMAN; MAMMOGRAPHY; MORTALITY; PUBLICATION; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; MASS SCREENING;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING;

EID: 84920774718     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12354     Document Type: Article

References (58)

1. Organizing Committee and Collaborators. Breast cancer screening with mammography in women aged 40-49 years. Report of the organizing committee and collaborators, Falun meeting, Falun, Sweden (21and 22 March, 1996). Int J Cancer 1996; 68: 693-9.
2. Smith RA, Duffy SW, Gabe R, Tabar L, Yen AM, Chen TH,. The randomized trials of breast cancer screening: what have we learned? Radiol Clin North Am 2004; 42: 793-806, v.
3. Tabar L, Fagerberg CJ, Gad A, et al,. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985; 1: 829-32.
4. Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O,. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am 1992; 30: 187-210.
5. Tabar L, Duffy SW, Vitak B, Chen HH, Prevost TC,. The natural history of breast carcinoma: what have we learned from screening? Cancer 1999; 86: 449-62.
6. NHS Breast Screening Programme. Annual Review 2012. Sheffield: NHS Cancer Screening Programmes, 2012.
7. Spiegelhalter DJ, Abrams KR, Myles JP,. Bayesian Approaches to Clinical Trials and Health Care Evaluation. Chichester: Wiley, 2004.
8. Thompson SG, Higgins JP,. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-73.
9. Freedman LS, Graubard BI, Schatzkin A,. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992; 11: 167-78.
10. Shapiro S, Venet W, Strax P, Venet L, Roeser R,. Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982; 69: 349-55.
11. Alexander FE, Anderson TJ, Brown HK, et al,. 14 years of follow-up from the Edinburgh randomised trial of breast- cancer screening [see comments]. Lancet 1999; 353: 1903-8.
12. Andersson I, Aspegren K, Janzon L, et al,. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 1988; 297: 943-8.
13. Andersson I, Janzon L,. Reduced breast cancer mortality in women under age 50: updated results from the Malmo Mammographic Screening Program. J Natl Cancer Inst Monogr 1997; 22: 63-7.
14. Bjurstam N, Bjorneld L, Warwick J, et al,. The Gothenburg Breast Screening Trial. Cancer 2003; 97: 2387-96.
15. Frisell J, Lidbrink E, Hellstrom L, Rutqvist LE,. Followup after 11 years-update of mortality results in the Stockholm mammographic screening trial. Breast Cancer Res Treat 1997; 45: 263-70.
16. Miller AB, Baines CJ, To T, Wall C,. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years [published erratum appears in Can Med Assoc J 1993 Mar 1;148(5):718] [see comments]. CMAJ 1992; 147: 1477-88.
17. Miller AB, Baines CJ, To T, Wall C,. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years [published erratum appears in Can Med Assoc J 1993 Mar 1;148(5):718] [see comments]. CMAJ 1992; 147: 1459-76.
18. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA,. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 2014; 348: g366.
19. Moss S, Waller M, Anderson TJ, Cuckle H,. Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures. Br J Cancer 2005; 92: 955-60.
20. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L,. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 2006; 368: 2053-60.
21. Duffy SW, Yen AM, Chen TH, et al,. Long-term benefits of breast screening. Breast Cancer Management 2012; 1: 31-8.
22. Gotzsche PC, Jorgensen KJ,. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2013; 6: CD001877.
23. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012; 380: 1778-86.
24. Morrison AS,. Intermediate determinants of mortality in the evaluation of screening. Int J Epidemiol 1991; 20: 642-50.
25. Elkin EB, Hudis C, Begg CB, Schrag D,. The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. Cancer 2005; 104: 1149-57.
26. Autier P, Hery C, Haukka J, Boniol M, Byrnes G,. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J Clin Oncol 2009; 27: 5919-23.
27. Swedish Organized Service Screening Evaluation Group. Effect of mammographic service screening on stage at presentation of breast cancers in Sweden. Cancer 2007; 109: 2205-12.
28. Autier P, Boniol M, Middleton R, et al,. Advanced breast cancer incidence following population-based mammographic screening. Ann Oncol 2011; 22: 1726-35.
29. Bleyer A, Welch HG,. Effect of three decades of screening mammography on breast cancer incidence. N Engl J Med 2012; 367: 1998-2005.
30. Kopans DB,. Point: The New England Journal of Medicine article suggesting overdiagnosis from mammography screening is scientifically incorrect and should be withdrawn. J Am Coll Radiol 2013; 10: 317-9; discussion 323.
31. Nederend J, Duijm LE, Voogd AC, Groenewoud JH, Jansen FH, Louwman MW,. Trends in incidence and detection of advanced breast cancer at biennial screening mammography in The Netherlands: a population based study. Breast Cancer Res 2012; 14: R10.
32. Anttila A, Sarkeala T, Hakulinen T, Heinavaara S,. Impacts of the Finnish service screening programme on breast cancer rates. BMC Public Health 2008; 8: 38.
33. Barchielli A, Paci E,. Trends in breast cancer mortality, incidence, and survival, and mammographic screening in Tuscany, Italy. Cancer Causes Control 2001; 12: 249-55.
34. Foca F, Mancini S, Bucchi L, et al,. Decreasing incidence of late-stage breast cancer after the introduction of organized mammography screening in Italy. Cancer 2013; 119: 2022-8.
35. Fracheboud J, Otto SJ, van Dijck JA, et al,. Decreased rates of advanced breast cancer due to mammography screening in The Netherlands. Br J Cancer 2004; 91: 861-7.
36. Hofvind S, Sorum R, Thoresen S,. Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program. Acta Oncol 2008; 47: 225-31.
37. Schouten LJ, de Rijke JM, Huveneers JA, Verbeek AL,. Rising incidence of breast cancer after completion of the first prevalent round of the breast cancer screening programme. J Med Screen 2002; 9: 120-4.
38. Broeders M, Moss S, Nystrom L, et al,. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen 2012; 19 (Suppl 1): 14-25.
39. Gabe R, Duffy SW,. Evaluation of service screening mammography in practice: the impact on breast cancer mortality. Ann Oncol 2005; 16 (Suppl 2): ii153-62.
40. Harris R, Yeatts J, Kinsinger L,. Breast cancer screening for women ages 50 to 69 years a systematic review of observational evidence. Prev Med 2011; 53: 108-14.
41. Irvin VL, Kaplan RM,. Screening mammography & breast cancer mortality: meta-analysis of quasi-experimental studies. PLoS ONE 2014; 9: e98105.
42. Nickson C, Mason KE, English DR, Kavanagh AM,. Mammographic screening and breast cancer mortality: a case-control study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012; 21: 1479-88.
43. 2Paap E, Verbeek A, Puliti D, Broeders M, Paci E,. Minor influence of self-selection bias on the effectiveness of breast cancer screening in case-control studies in the Netherlands. J Med Screen 2011; 18: 142-6.
44. Schopper D, de Wolf C,. How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer 2009; 45: 1916-23.
45. Walter SD,. Mammographic screening: case-control studies. Ann Oncol 2003; 14: 1190-2.
46. Welch HG,. Screening mammography-a long run for a short slide? N Engl J Med 2010; 363: 1276-8.
47. Aerts L, Christiaens MR, Enzlin P, Neven P, Amant F,. Sexual functioning in women after mastectomy versus breast conserving therapy for early-stage breast cancer: a prospective controlled study. Breast 2014; 23: 629-36.
48. Collins KK, Liu Y, Schootman M, et al,. Effects of breast cancer surgery and surgical side effects on body image over time. Breast Cancer Res Treat 2011; 126: 167-76.
49. Crosbie J, Kilbreath SL, Dylke E, et al,. Effects of mastectomy on shoulder and spinal kinematics during bilateral upper-limb movement. Phys Ther 2010; 90: 679-92.
50. Gho SA, Steele JR, Jones SC, Munro BJ,. Self-reported side effects of breast cancer treatment: a cross-sectional study of incidence, associations, and the influence of exercise. Cancer Causes Control 2013; 24: 517-28.
51. Hayes SC, Johansson K, Stout NL, et al,. Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer 2012; 118: 2237-49.
52. Schmitz KH, Speck RM, Rye SA, DiSipio T, Hayes SC,. Prevalence of breast cancer treatment sequelae over 6 years of follow-up: the Pulling Through Study. Cancer 2012; 118: 2217-25.
53. Ewertz M, Jensen AB,. Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol 2011; 50: 187-93.
54. Kaplan HG, Malmgren JA, Atwood MK,. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005. BMC Cancer 2011; 11: 260.
55. Smith AK, Conneely KN, Pace TW, et al,. Epigenetic changes associated with inflammation in breast cancer patients treated with chemotherapy. Brain Behav Immun 2014; 38: 227-36.
56. Hughes KS, Schnaper LA, Bellon JR, et al,. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013; 31: 2382-7.
57. Silverstein MJ, Waisman JR, Gierson ED, Colburn W, Gamagami P, Lewinsky BS,. Radiation therapy for intraductal carcinoma. Is it an equal alternative? Arch Surg 1991; 126: 424-8.
58. Tabar L, Lindhe N, Yen AM, et al,. Radiotherapy after surgery for small breast cancers of stellate appearance. In:, Tabar L, ed. Imaging of the Breast-Technical Aspects and Clinical Implication. Rijeka, Croatia: InTech, 2012: 217-24.